These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36802055)

  • 1. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage.
    Pitman JP; Payrat JM; Park MS; Liu K; Corash L; Benjamin RJ
    Transfusion; 2023 Apr; 63(4):711-723. PubMed ID: 36802055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.
    Richard P; Pouchol E; Sandid I; Aoustin L; Lefort C; Chartois AG; Baima A; Malard L; Bacquet C; Ferrera-Tourenc V; Gallian P; Laperche S; Bliem C; Morel P; Tiberghien P
    Vox Sang; 2024 Mar; 119(3):212-218. PubMed ID: 38152857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of 7-day amotosalen/ultraviolet A light pathogen-reduced platelets in Honduras: Impact on platelet availability in a lower middle-income country.
    Pedraza M; Mejia J; Pitman JP; Arriaga G
    Vox Sang; 2024 Dec; 119(12):1268-1277. PubMed ID: 39374943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network.
    Mertes PM; Tacquard C; Andreu G; Kientz D; Gross S; Malard L; Drouet C; Carlier M; Gachet C; Sandid I; Boudjedir K
    Transfusion; 2020 Mar; 60(3):507-512. PubMed ID: 30907010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems.
    Benjamin RJ; Braschler T; Weingand T; Corash LM
    Transfusion; 2017 Dec; 57(12):2946-2957. PubMed ID: 28840603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.
    Rosskopf K; Helmberg W; Schlenke P
    Transfusion; 2020 Sep; 60(9):2058-2066. PubMed ID: 32619068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
    Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
    Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
    Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats.
    Riccardi D; Raspollini E; Rebulla P; Pappalettera M; Marangoni F; Greppi N; Sirchia G
    Transfusion; 1997 May; 37(5):528-30. PubMed ID: 9149780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet transfusion practice and related transfusion reactions in a large teaching hospital.
    Liker M; Bojanić I; Plenković F; Lukić M; Tomac G; Raos M; Golubić Ćepulić B
    Transfus Clin Biol; 2022 Feb; 29(1):37-43. PubMed ID: 34411746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial contamination of platelets for transfusion: strategies for prevention.
    Levy JH; Neal MD; Herman JH
    Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.
    Cancelas JA; Genthe JR; Stolla M; Rugg N; Bailey SL; Nestheide S; Shaz B; Mack S; Schroeder K; Anani W; Szczepiorkowski ZM; Dumont LJ; Yegneswaran S; Corash L; Mufti N; Benjamin RJ; Erickson AC
    Transfusion; 2022 Aug; 62(8):1619-1629. PubMed ID: 35808974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.
    Haass KA; Sapiano MRP; Savinkina A; Kuehnert MJ; Basavaraju SV
    Transfus Med Rev; 2019 Apr; 33(2):84-91. PubMed ID: 30930009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet safety strategies in Japan: impact of short shelf life on the incidence of septic reactions.
    Satake M; Kozakai M; Matsumoto M; Matsubayashi K; Taira R; Goto N
    Transfusion; 2020 Apr; 60(4):731-738. PubMed ID: 32119134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.
    Prioli KM; Karp JK; Lyons NM; Chrebtow V; Herman JH; Pizzi LT
    Appl Health Econ Health Policy; 2018 Dec; 16(6):889-899. PubMed ID: 30062464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.